论文信息 - Quality of life after nivolumab treatment for head and neck cancer. - 字舞流文

Quality of life after nivolumab treatment for head and neck cancer.

[1] K. Harrington,et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[2] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[3] R. Motzer,et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[4] N. Yarom,et al. Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ‐H&N Module, Phase III , 2015, Head & neck.

[5] D. Osoba,et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites , 2014, Cancer.

[6] N. Yarom,et al. Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy — Update of the EORTC QLQ‐H&N35, Phase I , 2013, Head & neck.

[7] P. Fayers,et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. , 2000, European journal of cancer.